216 related articles for article (PubMed ID: 28431950)
1. Postoperative adjuvant chemotherapy is associated with a lower incidence of colorectal adenomas in patients with previous colorectal cancer.
Lee HS; Kim SB; Lee HJ; Park SJ; Hong SP; Cheon JH; Kim WH; Kim TI
Gastrointest Endosc; 2018 Mar; 87(3):688-694.e2. PubMed ID: 28431950
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer.
Kwon HY; Kim IK; Kang J; Sohn SK; Lee KY
Cancer Res Treat; 2016 Jul; 48(3):970-7. PubMed ID: 26511802
[TBL] [Abstract][Full Text] [Related]
3. Incidence and predictors of adenoma after surgery for colorectal cancer.
Marques-Antunes J; Libânio D; Gonçalves P; Dinis-Ribeiro M; Pimentel-Nunes P
Eur J Gastroenterol Hepatol; 2017 Aug; 29(8):932-938. PubMed ID: 28682984
[TBL] [Abstract][Full Text] [Related]
4. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
5. Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer.
Lee JH; Jeon SM; Hong SP; Cheon JH; Kim TI; Kim WH
Dig Liver Dis; 2012 Dec; 44(12):1042-7. PubMed ID: 22789400
[TBL] [Abstract][Full Text] [Related]
6. Association between poorly differentiated clusters and efficacy of 5-fluorouracil-based adjuvant chemotherapy in stage III colorectal cancer.
Tajima Y; Shimada Y; Kameyama H; Yagi R; Okamura T; Kobayashi T; Kosugi SI; Wakai T
Jpn J Clin Oncol; 2017 Apr; 47(4):313-320. PubMed ID: 28100684
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects.
Chen SP; Wu CC; Lin SZ; Kang JC; Su CC; Chen YL; Lin PC; Chiu SC; Pang CY; Harn HJ
Am J Clin Oncol; 2009 Apr; 32(2):122-6. PubMed ID: 19307944
[TBL] [Abstract][Full Text] [Related]
8. Colonoscopic surveillance after colorectal cancer resection: who needs more intensive follow-up?
Choe EK; Park KJ; Chung SJ; Moon SH; Ryoo SB; Oh HK
Digestion; 2015; 91(2):142-9. PubMed ID: 25677684
[TBL] [Abstract][Full Text] [Related]
9. The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer.
Crozier JE; McKee RF; McArdle CS; Angerson WJ; Anderson JH; Horgan PG; McMillan DC
Br J Cancer; 2006 Jun; 94(12):1833-6. PubMed ID: 16721360
[TBL] [Abstract][Full Text] [Related]
10. Incidence and risk factors of metachronous colorectal neoplasm after curative resection of colorectal cancer in Korean patients.
Lee SY; Kim BC; Han KS; Hong CW; Sohn DK; Park SC; Kim SY; Baek JY; Chang HJ; Kim DY; Oh JH
J Dig Dis; 2014 Jul; 15(7):367-76. PubMed ID: 24773758
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit.
Song K; Guo Y; Wang X; Cai H; Zheng W; Li N; Song X; Ao L; Guo Z; Zhao W
FASEB J; 2019 Jan; 33(1):151-162. PubMed ID: 29957060
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Adjuvant 5-Fluorouracil Therapy for Patients with EMAST-Positive Stage II/III Colorectal Cancer.
Hamaya Y; Guarinos C; Tseng-Rogenski SS; Iwaizumi M; Das R; Jover R; Castells A; Llor X; Andreu M; Carethers JM
PLoS One; 2015; 10(5):e0127591. PubMed ID: 25996601
[TBL] [Abstract][Full Text] [Related]
13. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma.
Elsaleh H; Iacopetta B
Clin Colorectal Cancer; 2001 Aug; 1(2):104-9. PubMed ID: 12445368
[TBL] [Abstract][Full Text] [Related]
14. Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer.
Ide T; Kitajima Y; Ohtaka K; Mitsuno M; Nakafusa Y; Miyazaki K
Oncol Rep; 2008 Jun; 19(6):1571-6. PubMed ID: 18497967
[TBL] [Abstract][Full Text] [Related]
15. Expression of astrocyte-elevated gene-1 indicates prognostic value of fluoropyrimidine-based adjuvant chemotherapy in resectable stage III colorectal cancer.
Lin LW; Lai PS; Chen YY; Chen CY
Pathol Int; 2021 Nov; 71(11):752-764. PubMed ID: 34528330
[TBL] [Abstract][Full Text] [Related]
16. FOLFOX as adjuvant chemotherapy after curative resection of distant metastases in patients with colorectal cancer.
Nozawa H; Kitayama J; Sunami E; Saito S; Kanazawa T; Kazama S; Yazawa K; Kawai K; Mori K; Nagawa H
Oncology; 2011; 80(1-2):84-91. PubMed ID: 21677451
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
Yamada H; Iinuma H; Watanabe T
Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
[TBL] [Abstract][Full Text] [Related]
18. Risk of colorectal cancer and adenomas in the families of patients with adenomas: a population-based study in Utah.
Tuohy TM; Rowe KG; Mineau GP; Pimentel R; Burt RW; Samadder NJ
Cancer; 2014 Jan; 120(1):35-42. PubMed ID: 24150925
[TBL] [Abstract][Full Text] [Related]
19.
Lapucci A; Perrone G; Di Paolo A; Napoli C; Landini I; Roviello G; Calosi L; Naccarato AG; Falcone A; Bani D; Mini E; Nobili S
Oncol Res; 2021 Mar; 28(6):631-644. PubMed ID: 33208224
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
